Understanding the global measurement of willingness to pay in health

References

• Grosse SD. Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res. 2008;8(2):165–10.
   PubMedGoogle Scholar
• Woods B, Revill P, Sculpher M, et al. Country-level cost-effectiveness thresholds: initial estimates and the need for further research. Value Health. 2016;19(8):929–935.
   PubMed Web of Science ®Google Scholar
• Marseille E, Larson B, Kazi DS, et al. Thresholds for the cost-effectiveness of interventions: alternative approaches. Bull World Health Organ. 2015;93(2):118–124.
   PubMed Web of Science ®Google Scholar
• WHO. Making choices in health: WHO guide to cost-effectiveness analysis. Tan-Torres Edejer T, Baltussen R, Adam T, Hutubessy R, Acharya A, Evans DB, Murray DB, Murray CJL, editors. Geneva: WHO; 2003.
   Google Scholar
• Hirth RA, Chernew ME, Miller E, et al. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making. 2000;20(3):332–342.
   PubMed Web of Science ®Google Scholar
• Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness–the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371(9):796–797.
   PubMed Web of Science ®Google Scholar
• Tufts Medical Center. Center for the evaluation of value and risk in health. Cost-effectiveness analysis registry. [cited 2017 Oct 22]. Available from: https://cevr.tuftsmedicalcenter.org/databases/cea-registry
   Google Scholar
• King JT Jr., Tsevat J, Lave JR, et al. Willingness to pay for a quality-adjusted life year: implications for societal health care resource allocation. Med Decis Making. 2005;25(6):667–677.
   PubMed Web of Science ®Google Scholar
• Jones-Lee M. The value of changes in the probability of death or injury. J Political Econ. 1974;82(4):835–849.
   Web of Science ®Google Scholar
• Pratt J, Zeckhauser R. Willingness to pay and the distribution of risk and wealth. J Political Econ. 1996;104(4):747–763.
   Web of Science ®Google Scholar
• Martin-Fernandez J, Polentinos-Castro E, Del Cura-Gonzalez MI, et al. Willingness to pay for a quality-adjusted life year: an evaluation of attitudes towards risk and preferences. BMC Health Serv Res. 2014;14:287.
   PubMed Web of Science ®Google Scholar
• Nimdet K, Chaiyakunapruk N, Vichansavakul K, et al. A systematic review of studies eliciting willingness-to-pay per quality-adjusted life year: does it justify CE threshold? PLoS One. 2015;10(4):e0122760.
   PubMed Web of Science ®Google Scholar
• Vallejo-Torres L, Garcia-Lorenzo B, Castilla I, et al. On the estimation of the cost-effectiveness threshold: why, what, how? Value Health. 2016;19(5):558–566.
   PubMed Web of Science ®Google Scholar
• Nanavaty M, Kaura S, Mwamburi M, et al. The use of incremental cost-effectiveness ratio thresholds in health technology assessment decisions. J Clin Pathways. 2015;1(1):29–36
   Google Scholar
• Google Finance. [cited 2017 Oct 22]. Available from: https://finance.google.com/finance?q=USDEU
   Google Scholar
• Lee G, Lee Y, Lee H, et al. Value of a statistical life estimation of carcinogenic chemicals for socioeconomic analysis in Korea. Environ Health Toxicol. 2015;30(Suppl):s2015005.
   Google Scholar
• Nimdet K, Ngorsuraches S. Willingness to pay per quality-adjusted life year for life-saving treatments in Thailand. BMJ Open. 2015;5(10):e008123.
   Web of Science ®Google Scholar
• Shafie AA, Lim YW, Chua GN, et al. Exploring the willingness to pay for a quality-adjusted life-year in the state of Penang, Malaysia. Clinicoecon Outcomes Res. 2014;6:473–481.
   Google Scholar
• Shiroiwa T, Igarashi A, Fukuda T, et al. WTP for a QALY and health states: more money for severer health states? Cost Eff Resour Alloc. 2013;11:22.
   PubMedGoogle Scholar
• Thavorncharoensap M, Teerawattananon Y, Natanant S, et al. Estimating the willingness to pay for a quality-adjusted life year in Thailand: does the context of health gain matter?. Clinicoecon Outcomes Res. 2013;5:29–36.
   PubMedGoogle Scholar
• Yang Z, Liu P, Xu X. Estimation of social value of statistical life using willingness-to-pay method in Nanjing, China. Accid Anal Prev. 2016;95(Pt B):308–316.
   Google Scholar
• Ahlert M, Breyer F, Schwettmann L. How you ask is what you get: framing effects in willingness-to-pay for a QALY. Soc Sci Med. 2016;150:40–48.
   PubMed Web of Science ®Google Scholar
• Bobinac A, Van Exel NJ, Rutten FF, et al. Willingness to pay for a quality-adjusted life-year: the individual perspective. Value Health. 2010;13(8):1046–1055.
   PubMed Web of Science ®Google Scholar
• Gyrd-Hansen D. Willingness to pay for a QALY. Health Econ. 2003;12(12):1049–1060.
   PubMed Web of Science ®Google Scholar
• Moradi N, Rashidian A. Willingness to pay for quality-adjusted life years in patients with diabete. Value Health. 2015;18(7):A617.
   Google Scholar
• Byrne MM, O’Malley K, Suarez-Almazor ME. Willingness to pay per quality-adjusted life year in a study of knee osteoarthritis. Med Decis Making. 2005;25(6):655–666.
   Web of Science ®Google Scholar
• Franic DM, Pathak DS, Gafni A. Quality-adjusted life years was a poor predictor of women’s willingness to pay in acute and chronic conditions: results of a survey. J Clin Epidemiol. 2005;58(3):291–303.
   PubMed Web of Science ®Google Scholar
• Haninger K, Hammitt JK. Diminishing willingness to pay per quality-adjusted life year: valuing acute foodborne illness. Risk Anal. 2011;31(9):1363–1380.
   PubMed Web of Science ®Google Scholar
• Lieu TA, Ray GT, Ortega-Sanchez IR, et al. Willingness to pay for a QALY based on community member and patient preferences for temporary health states associated with herpes zoster. Pharmacoeconomics. 2009;27(12):1005–1016.
   Web of Science ®Google Scholar
• Muller A, Reutzel TJ. Willingness to pay for reduction in fatality risk: an exploratory survey. Am J Public Health. 1984;74(8):808–812.
   PubMed Web of Science ®Google Scholar
• Shiroiwa T, Sung YK, Fukuda T, et al. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ. 2010;19(4):422–437.
   PubMed Web of Science ®Google Scholar
• Turnbull BW. The empirical distribution function with arbitrarily grouped, censored and truncated data. J R Stat Soc. 1976;38(3):290–295.
   Google Scholar
• Robinson A, Gyrd-Hansen D, Bacon P, et al. Estimating a WTP-based value of a QALY: the ‘chained’ approach. Soc Sci Med. 2013;92:92–104.
   PubMed Web of Science ®Google Scholar
• Cleemput I, Neyt M, Thiry N, et al. Using threshold values for cost per quality-adjusted life-year gained in healthcare decisions. Int J Technol Assess Health Care. 2011;27(1):71–76.
   PubMed Web of Science ®Google Scholar
• George B, Harris A, Mitchell A. Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in australia (1991 to 1996). Pharmacoeconomics. 2001;19(11):1103–1109.
   Web of Science ®Google Scholar
• Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ. 1992;146(4):473–481.
   PubMed Web of Science ®Google Scholar
• Rocchi A, Menon D, Verma S, et al. The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyond. Value Health. 2008;11(4):771–783.
   PubMed Web of Science ®Google Scholar
• Barry M, Tilson L. Recent developments in pricing and reimbursement of medicines in Ireland. Expert Rev Pharmacoecon Outcomes Res. 2007;7(6):605–611.
   Google Scholar
• Franken M, Koopmanschap M, Steenhoek A. Health economic evaluations in reimbursement decision making in the Netherlands: time to take it seriously? Z Evid Fortbild Qual Gesundhwes. 2014;108(7):383–389.
   PubMedGoogle Scholar
• Pauwels K, Huys I, Casteels M, et al. Market access of cancer drugs in European countries: improving resource allocation. Target Oncol. 2014;9(2):95–110.
   PubMed Web of Science ®Google Scholar
• Rodriguez JM, Paz S, Lizan L, et al. The use of quality-adjusted life-years in the economic evaluation of health technologies in Spain: a review of the 1990–2009 literature. Value Health. 2011;14(4):458–464.
   Web of Science ®Google Scholar
• Buxton MJ. Economic evaluation and decision making in the UK. Pharmacoeconomics. 2006;24(11):1133–1142.
   PubMed Web of Science ®Google Scholar
• Simoens S. How to assess the value of medicines? Front Pharmacol. 2010;1:115.
   Web of Science ®Google Scholar
• Trading Economics. GDP per capita. 2016 [cited 2017 Oct 22]. https://tradingeconomics.com/country-list/gdp-per-capita-ppp
   Google Scholar
• Bertram MY, Lauer JA, De Joncheere K, et al. Cost-effectiveness thresholds: pros and cons. Bull World Health Organ. 2016;94(12):925–930.
   PubMed Web of Science ®Google Scholar